Payment overview · 2025
General Payments
$49.71
3 reported records · 3 companies
Healthcare provider profile · identity verified
Kellen E Sherlock, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · WASHINGTON, KS · NPI 1518221662
Verified facts
What the public records show
CMS Open Payments records show Kellen E Sherlock, M.D. received $49.71 in general payments during 2025 across 3 reported records.
Baxter Healthcare accounted for 41.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 3 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported DALIRESP as an associated drug or biological on 54 records involving 42 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Daliresp by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Farxiga by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABRYSVO as an associated drug or biological on 55380 records involving 31565 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Abrysvo by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 230 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Baxter Healthcare | Unresolved — no canonical attribution shown | $20.39 | 41.0% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $15.79 | 31.8% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $13.53 | 27.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $49.71 | 3 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Hillrom - Cardiac Ambulatory Monitor Normalized: hillrom cardiac ambulatory monitor |
Device | Baxter Healthcare | $20.39 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $15.79 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $13.53 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 230 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | DALIRESP open payments reported associated product |
CMS Open Payments — General Payments 54 supporting records · 42 recipient NPIs · example record 1206139572 |
Daliresp · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
38 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ABRYSVO open payments reported associated product |
CMS Open Payments — General Payments 55380 supporting records · 31565 recipient NPIs · example record 1228794147 |
Abrysvo · 2024 Exact normalized brand match · 1 Part D row |
40 | 40 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
230 | 18 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 380 | 41 |
| Atorvastatin Calcium | Atorvastatin Calcium | 274 | 41 |
| Lisinopril | Lisinopril | 255 | 34 |
| Meloxicam | Meloxicam | 246 | 39 |
| Eliquis | Apixaban | 230 | 18 |
| Amlodipine Besylate | Amlodipine Besylate | 208 | 28 |
| Tamsulosin Hcl | Tamsulosin Hcl | 174 | 22 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 174 | 16 |
| Amlodipine-Atorvastatin | Amlodipine/Atorvastatin | 148 | 13 |
| Trazodone Hcl | Trazodone Hcl | 122 | 15 |
| Mounjaro | Tirzepatide | 119 | 12 |
| Clopidogrel | Clopidogrel Bisulfate | 115 | 11 |
| Gabapentin | Gabapentin | 112 | 19 |
| Losartan Potassium | Losartan Potassium | 105 | 16 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 103 | 16 |
| Finasteride | Finasteride | 93 | 12 |
| Metoprolol Succinate | Metoprolol Succinate | 91 | 14 |
| Omeprazole | Omeprazole | 86 | 19 |
| Sertraline Hcl | Sertraline Hcl | 80 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 79 | 22 |
| Duloxetine Hcl | Duloxetine Hcl | 77 | 13 |
| Pantoprazole Sodium | Pantoprazole Sodium | 76 | 12 |
| Metformin Hcl Er | Metformin Hcl | 72 | suppressed |
| Metformin Hcl | Metformin Hcl | 67 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 65 | 11 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 64 | 14 |
| Glipizide Er | Glipizide | 62 | suppressed |
| Simvastatin | Simvastatin | 60 | suppressed |
| Potassium Chloride | Potassium Chloride | 58 | suppressed |
| Famotidine | Famotidine | 55 | 11 |
| Tramadol Hcl | Tramadol Hcl | 55 | 14 |
| Montelukast Sodium | Montelukast Sodium | 52 | suppressed |
| Pregabalin | Pregabalin | 47 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 46 | 16 |
| Myrbetriq | Mirabegron | 45 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 44 | suppressed |
| Alprazolam | Alprazolam | 43 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 42 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 41 | suppressed |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 40 | 40 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 40 | suppressed |
| Omeprazole-Sodium Bicarbonate | Omeprazole/Sodium Bicarbonate | 40 | suppressed |
| Torsemide | Torsemide | 39 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 38 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 38 | suppressed |
| Clonazepam | Clonazepam | 36 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 36 | suppressed |
| Alprazolam Xr | Alprazolam | 35 | suppressed |
| Carvedilol | Carvedilol | 35 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 35 | suppressed |
| Invokana | Canagliflozin | 35 | suppressed |
| Ozempic | Semaglutide | 34 | suppressed |
| Quetiapine Fumarate Er | Quetiapine Fumarate | 34 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 32 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 32 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 32 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 32 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 32 | suppressed |
| Mirtazapine | Mirtazapine | 31 | suppressed |
| Celecoxib | Celecoxib | 29 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 29 | suppressed |
| Modafinil | Modafinil | 27 | suppressed |
| Aripiprazole | Aripiprazole | 26 | suppressed |
| Lansoprazole | Lansoprazole | 26 | suppressed |
| Edarbi | Azilsartan Medoxomil | 25 | suppressed |
| Gemtesa | Vibegron | 25 | suppressed |
| Prednisone | Prednisone | 25 | 22 |
| Xarelto | Rivaroxaban | 25 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 25 | suppressed |
| Glumetza | Metformin Hcl | 24 | suppressed |
| Metformin Er Gastric | Metformin Hcl | 24 | suppressed |
| Azithromycin | Azithromycin | 23 | 22 |
| Levetiracetam | Levetiracetam | 23 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 23 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 23 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 22 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 22 | 20 |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 22 | suppressed |
| Fentanyl | Fentanyl | 22 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 21 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 21 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 21 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 21 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 20 | suppressed |
| Bupropion Xl | Bupropion Hcl | 20 | suppressed |
| Furosemide | Furosemide | 20 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 20 | 13 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 19 | suppressed |
| Ibuprofen | Ibuprofen | 18 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 17 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 17 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 16 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 16 | suppressed |
| Roflumilast | Roflumilast | 16 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 16 | 12 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 15 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 15 | 11 |
| Zegerid | Omeprazole/Sodium Bicarbonate | 15 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 14 | suppressed |
| Candesartan Cilexetil | Candesartan Cilexetil | 14 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 14 | suppressed |
| Lorazepam | Lorazepam | 14 | suppressed |
| Repatha Syringe | Evolocumab | 14 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 14 | 12 |
| Verapamil Er | Verapamil Hcl | 14 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 13 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 13 | suppressed |
| Cartia Xt | Diltiazem Hcl | 13 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 13 | suppressed |
| Ezetimibe | Ezetimibe | 13 | suppressed |
| Irbesartan | Irbesartan | 13 | suppressed |
| Jardiance | Empagliflozin | 13 | suppressed |
| Lamotrigine Er | Lamotrigine | 13 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 13 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 13 | suppressed |
| Repatha Sureclick | Evolocumab | 13 | suppressed |
| Topiramate | Topiramate | 13 | suppressed |
| Anastrozole | Anastrozole | 12 | suppressed |
| Carisoprodol | Carisoprodol | 12 | suppressed |
| Cilostazol | Cilostazol | 12 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 12 | suppressed |
| Hydroxyurea | Hydroxyurea | 12 | suppressed |
| Levetiracetam Er | Levetiracetam | 12 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 12 | suppressed |
| Risperidone Odt | Risperidone | 12 | suppressed |
| Spironolactone | Spironolactone | 12 | suppressed |
| Valsartan | Valsartan | 12 | suppressed |
| Xtampza Er | Oxycodone Myristate | 12 | suppressed |
| Daliresp | Roflumilast | 11 | suppressed |
| Loperamide | Loperamide Hcl | 11 | suppressed |
| Risperidone | Risperidone | 11 | suppressed |
| Synthroid | Levothyroxine Sodium | 11 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 11 | suppressed |
| Victoza 3-Pak | Liraglutide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $49.71 · 3 records | Baxter Healthcare | AIRSUPRA, ELIQUIS, Hillrom - Cardiac Ambulatory Monitor | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error